Compile Data Set for Download or QSAR
maximum 50k data
Found 3197 with Last Name = 'lapointe' and Initial = 'bt'
LigandPNGBDBM50609728(CHEMBL5267350)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured afte...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
LigandPNGBDBM50609742(CHEMBL5286106)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assayMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
LigandPNGBDBM50609742(CHEMBL5286106)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of LRRK2 in human PBMCs assessed as reduction in Ser95 phosphorylationMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
LigandPNGBDBM50609741(CHEMBL5284341)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assayMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359544(4-{(6R or S)-1-({2- chloro-6-[1- (difluoromethyl)c...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359566((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359568((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359569((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM257207(US9493440, 51)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured afte...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523028(US11161854, Example 2.4-1 | US11161854, Example 2....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523096(US11161854, Example 4.20)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523095(US11161854, Example 4.19)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523093(US11161854, Example 4.17)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523092(US11161854, Example 4.16)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523088(US11161854, Example 4.13)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523087(US11161854, Example 4.12-2)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523040(US11161854, Example 3.3 | US11161854, Example 4.10)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523081(US11161854, Example 4.9-1 | US11161854, Example 4....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523081(US11161854, Example 4.9-1 | US11161854, Example 4....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523076(US11161854, Example 4.4)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523074(US11161854, Example 4.3-1 | US11161854, Example 4....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523072(US11161854, Example 4.1)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523069(US11161854, Example 3.11-2 | US11161854, Example 3...)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523061(US11161854, Example 3.8-4)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523051(US11161854, Example 3.6-2 | US11161854, Example 3....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523042(US11161854, Example 3.5-1 | US11161854, Example 3....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523038(US11161854, Example 3.1-2)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523034(US11161854, Example 2.7-1 | US11161854, Example 2....)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523131(US11161854, Example 11.2)
Affinity DataIC50:  0.600nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359571((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)c...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359543(4-[(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl)...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359545(4-{(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl)...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359548(4-{(6R or S)-1-({2- chloro-6-[1- (difluoromethyl)c...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359567((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359570((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.600nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523106(US11161854, Example 4.30)
Affinity DataIC50:  0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523104(US11161854, Example 4.28)
Affinity DataIC50:  0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359540(4-[(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl)...)
Affinity DataIC50:  0.700nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359582((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.700nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50609741(CHEMBL5284341)
Affinity DataIC50:  0.700nMAssay Description:Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured afte...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359547(4-[(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl)...)
Affinity DataIC50:  0.700nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523036(US11161854, Example 2.8-1 | US11161854, Example 2....)
Affinity DataIC50:  0.700nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359577(4-[(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl)...)
Affinity DataIC50:  0.700nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523109(US11161854, Example 5.3-1 | US11161854, Example 5....)
Affinity DataIC50:  0.700nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359535(US10221142, Example 21A)
Affinity DataIC50:  0.700nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523085(US11161854, Example 4.11-2)
Affinity DataIC50:  0.700nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359539(4-{(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl...)
Affinity DataIC50:  0.800nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [1-1200,1251-2527,G2019S](Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM523032(US11161854, Example 2.6-1 | US11161854, Example 2....)
Affinity DataIC50:  0.800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen™ technology from Life Technologies Corporation (Carlsbad, C...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359550(4-[(6R or S)-1-({2- chloro-6-[1- (difluoromethyl)c...)
Affinity DataIC50:  0.800nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359551(4-[(6R or S)-1-({2- chloro-6-[1- (difluoromethyl)c...)
Affinity DataIC50:  0.800nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 3197 total ) | Next | Last >>
Jump to: